Loading...
•
Dec 31, 2020
Royalty Pharma Q4 2020 Earnings Report
Royalty Pharma reported Q4 2020 earnings with growth in operating activities and Adjusted Cash Flow.
Key Takeaways
Royalty Pharma's Q4 2020 results showed an 18% increase in net cash provided by operating activities and a 9% increase in Adjusted Cash Receipts. The company also announced $2.4 billion in acquisitions for 2020 and increased its outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%.
Net cash provided by operating activities increased by 18% in Q4 2020.
Adjusted Cash Receipts grew by 9% to $484 million in Q4 2020.
Adjusted Cash Flow increased by 22% to $423 million in Q4 2020.
The company executed $2.4 billion of transactions spanning five therapeutic areas in 2020.
Revenue by Segment
Forward Guidance
Royalty Pharma anticipates full-year 2021 Adjusted Cash Receipts(1) to be between $1,910 million and $1,960 million, excluding new transactions announced subsequent to the date of this release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...